Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, TDS

CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September Conferences


ROCKVILLE, Md. and BEIJING, Sept. 11, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He, Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the following upcoming virtual conferences in September. Details for the virtual conferences are as follows.

H.C. Wainwright 22nd Annual Global Investment Conference
Date: Monday, September 14th
Time: 12:30 PM (EDT)

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Wednesday, September 23rd
Time: 1:40 PM (EDT)

Webcast or external link of the company presentations will be available under "Events & Presentations" in the "Investors Relations" section of CASI's website. Archived replays will be available for approximately 90 days following the event.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. ("CASI" or the "Company") is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. ("CASI China"), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.

COMPANY CONTACT:

CASI Pharmaceuticals, Inc.

240.864.2643

[email protected]

INVESTOR CONTACT:

Solebury Trout

Jennifer Porcelli

646.378.2962

[email protected]

SOURCE CASI Pharmaceuticals, Inc.


These press releases may also interest you

at 09:15
New Subscription Packages Provide Increased Client Value, Drive Higher Contract Values for DHI Group
New flat fee subscription packages from DHI Group, Inc. , parent company to Dice and ClearanceJobs, are providing greater value and flexibility for clients. The comprehensive hiring solutions in the packages, which offer unlimited job postings for...

at 09:15
Cedar Gate's Heart Disease & Heart Failure Predictive AI Models Could Save $1.4 Billion with Early Intervention
Cedar Gate Technologies (Cedar Gate) announced that an analysis of their national Healthcare Benchmark Database, encompassing nearly 13 million member lives, revealed a potential savings opportunity of approximately $1.4 billion. Machine learning...

at 09:15
New Relic Enhances AI Monitoring, Industry's First APM for AI
New Relic, the all-in-one observability platform for every engineer, announced the general availability of New Relic AI monitoring with a suite of powerful new features to meet the evolving needs of organizations developing AI applications. New...

at 09:13
Premier luxury hotel The Global Ambassador partners with global guest technology provider SONIFI
Arizona's newest luxury hotel, The Global Ambassador, delivers guests a convergence of hospitality, wellness and culture, complemented by seamless technology solutions from SONIFI, hospitality's largest guest technology provider....

at 09:11
Sustainable Projects Group Announces Partnership Agreement with Sunday Creek Horizons
Sustainable Projects Group Inc. ('Sustainable Projects Group' or the 'Company'), a green technology mining company focused on sustainable lithium projects in the United States, today announced that the Company's wholly owned subsidiary, Lithium...

at 09:10
IT Distribution Revenues Continued to Decline in Q1 as Personal Computing Spending Stabilized, According to the IDC North America Distribution Tracker, Powered by GTDC
IT distributor revenue experienced a year-on-year decline of 5.5% to $17.85 billion in the first quarter of 2024, according to the International Data Corporation (IDC) North America Distribution Tracker (NADT). The market continued to rebalance...

More news about Science and technology...


News published on and distributed by: